These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8158864)

  • 1. [Background of cardiovascular diseases in adult--with special reference to metabolic disorder of glucose and hypertension].
    Iimura O
    Nihon Ronen Igakkai Zasshi; 1994 Jan; 31(1):1-9. PubMed ID: 8158864
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypertension as a part of metabolic cardiovascular syndrome].
    Os I; Hjermann I; Nordby G
    Tidsskr Nor Laegeforen; 1991 Oct; 111(25):3062-4. PubMed ID: 1948918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.
    Russo E; Leoncini G; Esposito P; Garibotto G; Pontremoli R; Viazzi F
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise training in obese diabetic patients. Special considerations.
    Zierath JR; Wallberg-Henriksson H
    Sports Med; 1992 Sep; 14(3):171-89. PubMed ID: 1439393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of estimated insulin resistance and glucose intolerance to essential hypertension.
    Eriksson KF; Lindgärde F
    J Intern Med Suppl; 1991; 735():75-83. PubMed ID: 2043225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reduced glucose tolerance as a risk factor of cardiovascular diseases].
    Holmen J
    Tidsskr Nor Laegeforen; 1994 Jun; 114(15):1700-3. PubMed ID: 8079281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular dysmetabolic syndrome.
    Fagan TC; Deedwania PC
    Am J Med; 1998 Jul; 105(1A):77S-82S. PubMed ID: 9707273
    [No Abstract]   [Full Text] [Related]  

  • 8. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.
    Hernández-Mijares A; Jarabo-Bueno MM; López-Ruiz A; Solá-Izquierdo E; Morillas-Ariño C; Martínez-Triguero ML
    Int J Obes (Lond); 2007 Jun; 31(6):927-32. PubMed ID: 17264851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs and Cardiovascular Disease in Diabetes Mellitus.
    Ding Y; Sun X; Shan PF
    Biomed Res Int; 2017; 2017():4080364. PubMed ID: 28299324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Variations in certain endocrine and metabolic parameters after oral and intravenous administration of glucose and after a standard meal in obese patients with chemical diabetes mellitus].
    Gragnoli G; Tanganelli I; Favilli R; Martinelli G; Kristodhullu A
    Boll Soc Ital Biol Sper; 1977 Oct; 53(19):1627-33. PubMed ID: 607966
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.
    Sowers JR; Frohlich ED
    Med Clin North Am; 2004 Jan; 88(1):63-82. PubMed ID: 14871051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
    Zarich SW
    Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate metabolism, insulin resistance, and metabolic cardiovascular syndrome.
    Vaaler S
    J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S11-4. PubMed ID: 1283763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic characteristics of glucose intolerance: the critical role of obesity.
    Sainaghi PP; Castello L; Bergamasco L; Carnevale Schianca GP; Bartoli E
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):86-93. PubMed ID: 17972239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The metabolic syndrome].
    Ratzmann KP
    Z Arztl Fortbild (Jena); 1991 Jul; 85(14):651-6. PubMed ID: 1926931
    [No Abstract]   [Full Text] [Related]  

  • 16. Relation of aging and sex hormones to metabolic syndrome and cardiovascular disease.
    Guarner-Lans V; Rubio-Ruiz ME; Pérez-Torres I; Baños de MacCarthy G
    Exp Gerontol; 2011 Jul; 46(7):517-23. PubMed ID: 21397002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetics of the metabolic overlap syndrome.
    Scott J; Shoulders C; Navaratnam N; Aitman T
    Proc Nutr Soc; 2000 Aug; 59(3):439. PubMed ID: 10997670
    [No Abstract]   [Full Text] [Related]  

  • 19. [Functional kinetics of insulin, lipids and cortisol after intravenous glucose loading in the early stages of essential hypertension].
    Baumann R; Thybusch D; Gödicke W; Kleinau E; Bansi D
    Dtsch Gesundheitsw; 1971 Mar; 26(12):525-36. PubMed ID: 5554966
    [No Abstract]   [Full Text] [Related]  

  • 20. Transgenic approach toward leptin biology: the clinical implications of leptin for the treatment of obesity-associated diabetes and obesity-related hypertension.
    Masuzaki H; Ogawa Y; Aizawa-Abe M; Nakao K
    Endocr J; 2002 Apr; 49(2):109-19. PubMed ID: 12081228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.